Barclays Downgrades Moderna (MRNA) to Equalweight
Tweet Send to a Friend
Barclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


